Connect with us

Hi, what are you looking for?

Jewish Business News

Syndicated

Paid Hepatic Impairment Clinical Trial Now Open at Avail Clinical Research Near Orlando, Florida

Avail is conducting a phase 1, pharmacokinetic and pharmacodynamic study of a single dose of an experimental drug in subjects with hepatic impairment.

Avail is conducting a phase 1, pharmacokinetic and pharmacodynamic study of a single dose of an experimental drug in subjects with hepatic impairment.

Online PR News – 13-June-2014 – To see if you qualify for this Hepatic Impairment Clinical Trial in DeLand, visit Avail Clinical Research on the web (http://www.availclinical.com) or contact us directly at (386) 785-2404. There is no cost to participate, no insurance is required, and you may receive compensation for time and travel.

STUDY DESIGN

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.

This is an open-label, parallel-group study to compare the pharmacokinetics and pharmacodynamics of a new hepatic function drug following a single 50 mg oral dose of the medication in subjects with mild, moderate, and severe hepatic impairment (defined as Child-Pugh A, B, and C, respectively) and matched healthy volunteers with normal hepatic function. Depending on the data from the 50 mg dose groups, a lower dose of this medication may be studied in additional groups of subjects with hepatic impairment.

BACKGROUND & RATIONALE

This clinical study is being undertaken to evaluate the pharmacokinetics of a single 50 mg dose of an experimental medication in subjects with hepatic impairment (defined as Child-Pugh A, B, and C, respectively) compared tomatched healthy volunteers, with the option to study a lower dose of this new drug in subjects with hepatic impairment based on emerging data. The data from this study will help inform researchers of the safety of this new medication in subjects with hepatic impairment, and address whether dose adjustment is required in this subject population.

Researchers intend to pursue studies in subjects with acute and chronic liver disease. It is anticipated that the data obtained from this study will allow them to expand the study population in future, and possibly, in ongoing studies to include those with severe hepatic impairment.

PRIMARY OBJECTIVES

To assess the pharmacokinetics and pharmacodynamics of a single oral dose of this new drug in subjects with hepatic impairment compared to that in matched healthy volunteers.

To assess the safety and tolerability of the experimental medication in subjects with hepatic impairment.

INCLUSION CRITERIA

All Subjects:

Male or female subjects 18 years of age or older, able to provide written informed consent, understand and comply with all scheduled visits, and other requirements of the study

Body mass index (BMI) 18.0 40.0 kg/m2 and body weight greater than 45 kg

Willingness to utilize two reliable forms of contraception (for both males and females of childbearing potential) from Screening to one month after the last dose of study drug

Matched Healthy Volunteers:

– Medically healthy as determined by the Investigator

– Supine blood pressure less than or equal to 145/90 mmHg

– No significant uncontrolled systemic or major illness that, in the opinion of the

– Investigator, would preclude the subject from participating in and completing the study

Advertisement. Scroll to continue reading.

Demographically comparable to subjects with hepatic impairment as follows:

– Mean body weight within 15 kg

– Mean age within 10 years

– Similar gender ratio

Subjects with Hepatic Impairment:

– Evidence of hepatic disease:

– Score greater than or equal to 2 on one of the Child-Pugh parameters, or

– Histological or imaging diagnosis of cirrhosis, or

– Presence of esophageal varices, or

– Abnormal alanine aminotransferase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP) levels

Meet one of the following criteria for Child-Pugh classification for hepatic impairment during Screening:

– Mild hepatic impairment: Class A (Child-Pugh Scores 5-6 points)

– Moderate hepatic impairment: Class B (Child-Pugh Scores 7-9 points)

– Severe hepatic impairment: Class C (Child Pugh Scores 10-15 points)

– Supine blood pressure less than or equal to 160/100 mmHg

Avail Clinical Research conducts a variety of Clinical Research Studies in Florida. For more information about participating in a Hepatic Impairment Clinical Trial, please visit our website or contact us directly at (386) 785-2404.

Company Contact Information
Jennifer Economou
http://www.availclinical.com
+1 (386) 785-2404
 

Newsletter



Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

Entertainment

The Movie The Professional is what made Natalie Portman a Lolita.

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.